Diagnostics platform Redcliffe Labs has reported a 20% year-on-year increase in operating revenue to ₹419 crore in FY25, up from ₹350 crore in the previous fiscal, according to a press release issued by the company. The Gurugram-based firm also narrowed its EBITDA losses from -38% in FY24 to -21% in FY25, signaling improving operational efficiency.
Founded by Aditya Kandoi, Redcliffe Labs operates a nationwide network of over 80 labs and claims to offer the widest home sample collection footprint in India. The company said diagnostic services accounted for over 95% of its FY25 revenue, with the remainder coming from product sales and other income.
Redcliffe said it diagnosed over 2.5 million cases last fiscal and continues to focus on underserved regions, with more than 70% of testing volumes originating from Tier II cities and beyond.
On the margins front, the company reported a gross margin of 70% in FY25 and is targeting a rise to 74% in FY26. It has also set a revenue target of ₹560 crore for the current fiscal year, driven by a combination of organic growth and strategic acquisitions.
“We are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,” said founder and CEO Aditya Kandoi.
Looking ahead, Redcliffe aims to expand its footprint to over 300 cities with 150 labs by FY28.
According to startup intelligence platform TheKredible, the company has raised $113 million to date, including a $42 million Series C round led by LeapFrog Investments. Redcliffe also acquired Bengaluru-based Celara Diagnostics in a $7 million deal to strengthen its presence in southern India.
Redcliffe competes with major players in the diagnostics space, including PharmEasy-owned Thyrocare, which reported ₹687 crore in revenue and ₹91 crore profit in FY25; Tata 1mg, which posted ₹1,968 crore in revenue in FY24; and Healthians, which recorded ₹250 crore topline in the same period.
